Holen Sie sich die Stockscreener-App
2.00
10.31%
-0.23
Vorhandelsmarkt:
2.05
0.05
+2.50%
Schlusskurs vom Vortag:
$2.23
Offen:
$2.25
24-Stunden-Volumen:
1.72M
Relative Volume:
1.87
Marktkapitalisierung:
$202.42M
Einnahmen:
$100.56M
Nettoeinkommen (Verlust:
$-119.05M
KGV:
-1.626
EPS:
-1.23
Netto-Cashflow:
$-231.16M
1W Leistung:
+28.21%
1M Leistung:
+24.22%
6M Leistung:
+21.95%
1J Leistung:
-60.82%
1-Tages-Spanne:
$1.99
$2.30
1-Wochen-Bereich:
$1.42
$2.415
52-Wochen-Spanne:
$0.87
$6.37
Alector Inc Stock (ALEC) Company Profile
Firmenname
Alector Inc
Sektor
Branche
Telefon
415-231-5660
Adresse
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Vergleichen Sie ALEC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
2.00 | 225.70M | 100.56M | -119.05M | -231.16M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-17 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-11-29 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-26 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-14 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-09-25 | Eingeleitet | Goldman | Sell |
| 2023-09-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-13 | Eingeleitet | Goldman | Sell |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-27 | Eingeleitet | William Blair | Outperform |
| 2021-01-15 | Fortgesetzt | BofA Securities | Buy |
| 2020-06-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Goldman | Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-19 | Eingeleitet | Stifel | Buy |
| 2019-11-21 | Eingeleitet | BTIG Research | Buy |
| 2019-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-03-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-03-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Alector Inc Aktie (ALEC) Neueste Nachrichten
Alector, Inc. (NASDAQ:ALEC) Q2 2025 Earnings Call Transcript - Insider Monkey
Is Alector Inc.’s growth already priced inFree Investment Consultation - mustnews.co.kr
3 Promising Penny Stocks With Market Caps Above $200M - simplywall.st
Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates - MSN
Alector (ALEC): A High-Conviction Biotech Play with Near-Term Catalysts and a Clear Path to Value Creation - AInvest
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update - ADVFN Brasil
Alector 2025 Q2 Earnings Continued Losses Despite Narrowing Net Income - AInvest
Transcript : Alector, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Alector's 30% Surge: A Biotech Breakout or a Volatility Trap? - AInvest
Promising Advancements in Alector’s Clinical Trials Highlighted by Positive Biomarker Data and Therapeutic Potential - TipRanks
H.C. Wainwright Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
BofA Securities Maintains Alector(ALEC.US) With Sell Rating, Maintains Target Price $1 - 富途牛牛
Alector Tightens Losses As Analysts Set Sights Higher - Finimize
Earnings call transcript: Alector beats Q2 2025 EPS and revenue forecasts - Investing.com
Alector's Q2 Earnings Call: Promising Progress in Dementia Trials Amidst Strategic Challenges - AInvest
Alector's Promising Future: Buy Rating Backed by FDA-Endorsed Trials and Amendments - AInvest
Alector Inc (ALEC) Q2 2025 Earnings Call Highlights: Promising Advances in Dementia Trials ... By GuruFocus - Investing.com Canada
Alector Inc (ALEC) Q2 2025 Earnings Call Highlights: Promising Advances in Dementia Trials Amidst Strategic Challenges - GuruFocus
Alector Inc (ALEC) Q2 2025 Earnings Call Highlights: Promising A - GuruFocus
Alector Advances Neurodegenerative Therapies Amid Financial Updates - TipRanks
Alector: Q2 Earnings Snapshot - Chron
Promising Developments and Strong Financials Make Alector a Compelling Buy - TipRanks
Alector’s Promising Future: Buy Rating Backed by Strategic Trials and FDA-Endorsed Amendments - TipRanks
Alector (ALEC) Q2 Revenue Falls 48% - The Globe and Mail
Alector earnings beat by $0.17, revenue topped estimates By Investing.com - Investing.com South Africa
Alector sees FY25 revenue view $13M-$18M, consensus $12.56M - TipRanks
Alector earnings beat by $0.17, revenue topped estimates - Investing.com Canada
Alector: A Biotech Gem Navigating the Post-IRA Landscape with Robust Financials and Promising Pipeline - AInvest
Alector Nears Crucial Phase 3 Results for First-Ever FTD Treatment as Cash Hits $307M - Stock Titan
Should I hold or sell Alector Inc. stock in 2025Invest smarter with daily stock recommendations - Jammu Links News
What makes Alector Inc. stock price move sharplyBoost your wealth with consistent growth stocks - Jammu Links News
How strong is Alector Inc. company’s balance sheetTremendous wealth creation - Jammu Links News
What institutional investors are buying Alector Inc. stockPowerful profit generation - Jammu Links News
Is Alector Inc. a good long term investmentInvest smarter with actionable market insights - Jammu Links News
How does Alector Inc. generate profit in a changing economyAchieve breakthrough financial results today - Jammu Links News
What is the dividend policy of Alector Inc. stockIdentify undervalued stocks ready to soar - Jammu Links News
What is Alector Inc. company’s growth strategyBuild a diversified portfolio for stability - Jammu Links News
Alector Inc. Stock Analysis and ForecastGet exclusive access to professional stock picks - Jammu Links News
How does Alector Inc. compare to its industry peersDiscover high-impact stocks for growth - Jammu Links News
Is it the right time to buy Alector Inc. stockHigh-yield investments - Jammu Links News
Why is Alector Inc. stock attracting strong analyst attentionAchieve rapid financial growth with smart picks - Jammu Links News
What are analysts’ price targets for Alector Inc. in the next 12 monthsBuild a diversified portfolio for steady profits - Jammu Links News
Alector’s Latozinemab Study: A Promising Step in Neurodegenerative Disease Treatment - The Globe and Mail
How to build a custom watchlist for Alector Inc.Sector Rotation Strategy for Smart Traders - Newser
Market reaction to Alector Inc.’s recent newsRSI and MACD Signal Summary with Trends - Newser
Identifying reversal signals in Alector Inc.Free AI Powered High Return Stock Calls - Newser
Why Alector Inc. stock attracts strong analyst attentionPortfolio Risk Distribution Analysis Tool - Newser
Alector Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Alector's Latozinemab Study Advances Neurodegenerative Disease Treatment - AInvest
When is Alector Inc. stock expected to show significant growthExpert Picks Watchlist For Every Investor - Jammu Links News
Finanzdaten der Alector Inc-Aktie (ALEC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):